Area of research
Nephrology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Diabetes Treatment and Management, Chronic Kidney Disease and Diabetes, Blood Pressure and Hypertension Studies, and Pancreatic function and diabetes.
Finerenone in Type 1 Diabetes and Chronic Kidney Disease
WCN26-2797 Impact of Polypharmacy on the Efficacy and Safety of SGLT2 Inhibitors in Patients with Chronic Kidney Disease: Insights from the CREDENCE trial
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the <scp>SURMOUNT</scp> ‐ <scp>MMO</scp> trial
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension
Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Combination therapy for kidney disease in people with diabetes mellitus
Atrasentan in Patients with IgA Nephropathy
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease
Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial
Endothelin receptor antagonists in chronic kidney disease
Combination Treatment with Verinurad and Allopurinol in CKD
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy
Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design
A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
Proteomic Analysis Uncovers Multiprotein Signatures Associated with Early Diabetic Kidney Disease in Youth with Type 2 Diabetes Mellitus
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial